Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 13/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21652875 | 0.90 | LRRK2 (0.39) | LRRK2ARPTPN11KCNQ3KCNQ2 | |
| SCHEMBL21653254 | 0.89 | LRRK2 (0.37) | LRRK2ARXDHROCK2ROCK1 | |
| SCHEMBL21653242 | 0.87 | LRRK2 (0.40) | LRRK2ARPTPN11KCNQ3KCNQ2 | |
| SCHEMBL21653259 | 0.85 | BACE1 (0.39) | PTPN11KCNQ3KCNQ2ROCK2ROCK1 | |
| SCHEMBL21653232 | 0.81 | MAPT (0.34) | AR | |
| SCHEMBL21653261 | 0.77 | LRRK2 (0.39) | LRRK2 | |
| SCHEMBL21653264 | 0.77 | MAPT (0.36) | AR | |
| SCHEMBL21653225 | 0.76 | ROCK2 (0.40) | PTPN11KCNQ3KCNQ2ROCK2ROCK1 | |
| SCHEMBL21653075 | 0.76 | KMT2A (0.36) | ROCK2ROCK1 | |
| SCHEMBL21652879 | 0.76 | LRRK2 (0.40) | LRRK2FSCN1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356174-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme, Inc. (US) | 2022-11-10 | — | — | US | disclosed |
| EP-3826999-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme Inc (US) | 2021-06-02 | — | — | EP | disclosed |
| CN-112739690-A | Pyridin-2-one compounds as SMARCA2 antagonists | 埃皮兹姆公司 | 2021-04-30 | — | — | CN | disclosed |
| WO-2020023657-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020023657-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356174-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | SMARCC1, SMARCC2, SMARCE1 | LRRK2 2337/4885AR 1182/4885PGR 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.